Opioid risk assessment
Risk assessment
Structured assessment of medical, social and family history — the thing the federal Task Force actually recommended, done properly rather than as a checkbox.
Why do doctors do a risk assessment before prescribing opioids?
The Comprehensive Addiction and Recovery Act of 2016 created the Pain Management Best Practices Inter-Agency Task Force, whose recommendations included safer opioid stewardship through risk assessment based on patients’ medical, social and family history to ensure safe and appropriate prescribing. That is a specific instruction and it is a good one. It is also not what usually happens, because doing it takes time and the alternative — reading a dose number — takes none.
Note what the recommendation is for: appropriate prescribing. Not exclusion. A risk assessment that only ever produces reasons to withhold treatment is not implementing this recommendation; it is using its vocabulary.
What does an opioid risk assessment include?
- Medical history — the pain diagnosis, comorbidity, prior therapy tried and its result, and the non-opioid load, including NSAID and acetaminophen exposure that the federal material specifically flags for renal, gastric, cardiac and hepatic risk.
- Behavioral health — via validated instruments rather than impression.
- Social circumstances — via social determinants verification, because they determine whether an intervention can work at all.
- Family history, as the Task Force recommendation specifies.
- Co-prescriptions, including non-scheduled medication that contributes to sedation.
The output is a picture with actions attached: what support this person needs, what needs clinical follow-up, what should be avoided. Not a score.
Can an opioid risk assessment be used to deny treatment or force a taper?
It is not a risk score that decides who gets treatment. The purpose is to determine what support a patient needs, not whether they deserve care.
It is not a permanent label. Circumstances change, and an assessment that is never revisited becomes a stereotype attached to a person.
It is not shared with an agency at the individual level, and it is not a case-building instrument.
It is not used to justify a taper. CDC’s 2022 guideline is explicit that patients should not be dismissed on the basis of monitoring or toxicology information, and the same logic applies here.
A limitation the federal material states and we repeat: clinicians must recognize the limits of screening tools in detecting prior or developing substance use disorder. A structured assessment organizes clinical judgment. It does not replace it, and a reassuring assessment is not a clearance. Separately, the AHRQ review found no study evaluating whether risk assessment instruments actually reduce overdose, addiction, abuse or misuse — see what is not established.
Frequently asked questions
Is an opioid risk assessment just a score?
No. The output is a picture with actions attached: what support the person needs, what needs clinical follow-up and what should be avoided. It is not a score, and it does not decide who gets treatment. The federal Task Force recommendation it follows was written to support appropriate prescribing, not exclusion.
Which medications are reviewed in an opioid risk assessment?
The review covers prior therapy and its result, co-prescriptions including non-scheduled medication that contributes to sedation, and the non-opioid load. That includes NSAID and acetaminophen exposure, which the federal material specifically flags for kidney, stomach, heart and liver risk. Behavioral health and social circumstances are assessed alongside the medication history.
Can a risk assessment be used to taper or dismiss a patient?
No. It is not used to justify a taper. The CDC’s 2022 guideline is explicit that patients should not be dismissed on the basis of monitoring or toxicology information, and the same logic applies here. The purpose is to decide what support a patient needs, not whether they deserve care.
Is my opioid risk assessment permanent?
No. Circumstances change, and an assessment that is never revisited becomes a stereotype attached to a person, so it is revisited rather than filed as a permanent label. It is also not shared with an agency at the individual level, and it is not a case-building instrument.
Does a reassuring risk assessment mean I cannot develop an addiction?
No. Screening tools have known limits in detecting prior or developing substance use disorder, and the federal material says clinicians must recognize those limits. A structured assessment organizes clinical judgment; it does not replace it. A reassuring assessment is not a clearance, and your clinician keeps watching for change.
Sources
Every figure on this page is traceable to the source listed here.
- National Academies of Sciences, Engineering, and Medicine. Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use. Bonnie RJ, Ford MA, Phillips JK, editors. Washington, DC: The National Academies Press; 2017. View source.
- Chou R, Hartung D, Turner J, Blazina I, Chan B, Levander X, McDonagh M, Selph S, Fu R, Pappas M. Opioid Treatments for Chronic Pain. Comparative Effectiveness Review No. 229. AHRQ Publication No. 20-EHC011. Rockville, MD: Agency for Healthcare Research and Quality; April 2020. View source.
- Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC clinical practice guideline for prescribing opioids for pain — United States, 2022. MMWR Recomm Rep. 2022;71(3):1–95. PMID 36327391. View source.